MX352641B - Vacuna contra pcv2 basada en peptidos de diseño. - Google Patents
Vacuna contra pcv2 basada en peptidos de diseño.Info
- Publication number
- MX352641B MX352641B MX2013000316A MX2013000316A MX352641B MX 352641 B MX352641 B MX 352641B MX 2013000316 A MX2013000316 A MX 2013000316A MX 2013000316 A MX2013000316 A MX 2013000316A MX 352641 B MX352641 B MX 352641B
- Authority
- MX
- Mexico
- Prior art keywords
- pcv2
- peptide antigen
- vaccine
- pcv2 vaccine
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La presente invención se refiere a composiciones de vacunas de circovirus porcino (PCV2) que comprenden un antígeno peptídico derivado de una proteína de la cápside de PCV2. En diversas modalidades, el antígeno peptídico contiene aminoácidos de la proteína de la cápside de aproximadamente el aminoácido 47 a aproximadamente el aminoácido 202. En algunas modalidades, el antígeno peptídico se enlaza opcionalmente a un epítopo de célula T cooperadora artificial y/o se mezcla con epítopos de célula T cooperadora derivados de las proteínas del ORF1 y ORF3 del PCV2. Los métodos para utilizar composiciones de vacunas de PCV2 también se describen. En diversas modalidades, una composición de vacuna se utiliza en animales para la prevención de la infección por PCV2. En otras modalidades, una composición de vacuna de PCV2 se utiliza como antígeno para diagnosticar la infección por PCV2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/041406 WO2012005732A1 (en) | 2010-07-08 | 2010-07-08 | Designer peptide-based pcv2 vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013000316A MX2013000316A (es) | 2013-02-26 |
MX352641B true MX352641B (es) | 2017-12-01 |
Family
ID=45441469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000316A MX352641B (es) | 2010-07-08 | 2010-07-08 | Vacuna contra pcv2 basada en peptidos de diseño. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9932372B2 (es) |
EP (1) | EP2590673A4 (es) |
JP (1) | JP5902160B2 (es) |
KR (1) | KR101675185B1 (es) |
CN (1) | CN103108653B (es) |
AU (2) | AU2010357208A1 (es) |
BR (1) | BR112013001231A2 (es) |
CA (1) | CA2804604C (es) |
MX (1) | MX352641B (es) |
TW (1) | TWI508740B (es) |
WO (1) | WO2012005732A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9932372B2 (en) * | 2010-07-08 | 2018-04-03 | United Biomedical, Inc. | Designer peptide-based PCV2 vaccine |
EP3052516B1 (en) | 2013-10-02 | 2020-01-01 | Boehringer Ingelheim Animal Health USA Inc. | Pcv2 orf2 protein variant and virus like particles composed thereof |
CN103805573A (zh) * | 2013-12-31 | 2014-05-21 | 广东大华农动物保健品股份有限公司 | 一种重组腺病毒rAd-ORF2-TCE及其应用 |
EP3277315A2 (en) * | 2015-03-30 | 2018-02-07 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 carrier platform |
CN105175551B (zh) * | 2015-07-01 | 2019-04-02 | 重庆市格晟生物技术有限责任公司 | 一种抗伪狂犬病毒合成肽疫苗及其用途 |
CN105175550B (zh) * | 2015-07-01 | 2019-04-02 | 重庆市格晟生物技术有限责任公司 | 一种抗猪圆环病毒合成肽疫苗及其用途 |
CN105175552B (zh) * | 2015-07-01 | 2019-04-02 | 重庆市格晟生物技术有限责任公司 | 一种刺激滤泡辅助型cd4t细胞应答的表位组合及其用途 |
CN105004856A (zh) * | 2015-07-10 | 2015-10-28 | 青岛易邦生物工程有限公司 | 猪圆环病毒2型抗体检测elisa试剂盒 |
CN105541976B (zh) * | 2015-12-25 | 2019-07-09 | 华南农业大学 | 猪圆环病毒2型Cap基因修饰改造重组抗原及其应用 |
CN107190012A (zh) * | 2016-03-14 | 2017-09-22 | 苏州派动生物技术有限公司 | 重组改构猪圆环病毒衣壳蛋白 |
CN106380509B (zh) * | 2016-08-29 | 2019-07-26 | 中牧实业股份有限公司 | 一种猪圆环合成肽疫苗及其制备方法和应用 |
CN107056897B (zh) * | 2017-01-22 | 2020-08-25 | 中牧实业股份有限公司 | 猪圆环合成肽疫苗及其制备方法和应用 |
EP4007601A4 (en) * | 2019-07-26 | 2023-08-09 | NDSU Research Foundation | PORCINE CIRCOVIRUS TYPE 2 (PCV2) VACCINE |
CN112010949B (zh) * | 2020-08-03 | 2021-07-27 | 山东绿都生物科技有限公司 | 一种重组pcv2病毒样颗粒蜂胶疫苗及其制备方法 |
CN115947794A (zh) * | 2022-07-19 | 2023-04-11 | 沈阳农业大学 | 一种pcv2 orf3特异性多肽及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
CA2313806A1 (en) | 1997-12-11 | 1999-06-17 | University Of Saskatchewan | Postweaning multisystemic wasting syndrome virus from pigs |
US6107021A (en) | 1998-06-20 | 2000-08-22 | United Biomedical, Inc. | Synthetic peptide vaccines for foot-and-mouth disease |
TWI229679B (en) | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
US6025468A (en) | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
CN1137727C (zh) | 1998-06-25 | 2004-02-11 | 四川远大蜀阳药业有限公司 | 无保护剂双重病毒灭活制备静注免疫球蛋白工艺 |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
US7279166B2 (en) * | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
JP2006528647A (ja) * | 2003-07-24 | 2006-12-21 | メリアル リミテッド | 新規ワクチン製剤 |
CN1602962A (zh) | 2004-08-04 | 2005-04-06 | 任兆钧 | 口蹄疫全病毒基因工程疫苗及其制备方法 |
US7833707B2 (en) * | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
JP5106398B2 (ja) | 2005-09-09 | 2012-12-26 | インターベツト・インターナシヨナル・ベー・ベー | Pcv−2ワクチン |
HUE029552T2 (en) | 2005-12-29 | 2017-03-28 | Boehringer Ingelheim Vetmedica Inc | Use of PCV2 immunogenic composition to reduce clinical symptoms in piglets |
US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
BRPI0721083A2 (pt) | 2006-12-15 | 2014-02-25 | Boehringer Ingelheim Vetmed | Tratamento de porcos com antígeno de pcv2 |
EP1958644A1 (en) * | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) * | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
FR2922767B1 (fr) * | 2007-10-24 | 2009-12-18 | Seppic Sa | Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant. |
CL2008003813A1 (es) * | 2007-12-21 | 2009-03-20 | Zoetis W Llc | Circovirus porcino; molecula de acido nucleico que lo codifica; composicion inmunogenica que lo comprende; metodo para inmunizar un cerdo contra la infeccion virica o para prevenir el sindrome postdestete de desgaste multi-sistemico (pmsw);y metodo para determinar si un mamifero tiene o esta en riesgo de desarrollar pmsw. |
US9932372B2 (en) * | 2010-07-08 | 2018-04-03 | United Biomedical, Inc. | Designer peptide-based PCV2 vaccine |
-
2010
- 2010-07-08 US US13/808,974 patent/US9932372B2/en active Active
- 2010-07-08 CN CN201080068977.7A patent/CN103108653B/zh active Active
- 2010-07-08 WO PCT/US2010/041406 patent/WO2012005732A1/en active Application Filing
- 2010-07-08 BR BR112013001231A patent/BR112013001231A2/pt not_active Application Discontinuation
- 2010-07-08 EP EP10854531.0A patent/EP2590673A4/en active Pending
- 2010-07-08 CA CA2804604A patent/CA2804604C/en active Active
- 2010-07-08 JP JP2013518361A patent/JP5902160B2/ja not_active Expired - Fee Related
- 2010-07-08 AU AU2010357208A patent/AU2010357208A1/en not_active Abandoned
- 2010-07-08 KR KR1020137003210A patent/KR101675185B1/ko active IP Right Grant
- 2010-07-08 MX MX2013000316A patent/MX352641B/es active IP Right Grant
-
2011
- 2011-07-04 TW TW100123478A patent/TWI508740B/zh active
-
2016
- 2016-08-29 AU AU2016219738A patent/AU2016219738B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201201833A (en) | 2012-01-16 |
JP2013531673A (ja) | 2013-08-08 |
EP2590673A4 (en) | 2016-03-30 |
AU2010357208A1 (en) | 2013-02-21 |
US20130236487A1 (en) | 2013-09-12 |
KR101675185B1 (ko) | 2016-11-10 |
AU2016219738A1 (en) | 2016-09-15 |
KR20130041185A (ko) | 2013-04-24 |
TWI508740B (zh) | 2015-11-21 |
WO2012005732A1 (en) | 2012-01-12 |
US9932372B2 (en) | 2018-04-03 |
CA2804604C (en) | 2023-10-03 |
CN103108653A (zh) | 2013-05-15 |
CN103108653B (zh) | 2015-07-22 |
JP5902160B2 (ja) | 2016-04-13 |
CA2804604A1 (en) | 2012-01-12 |
BR112013001231A2 (pt) | 2016-06-07 |
EP2590673A1 (en) | 2013-05-15 |
AU2016219738B2 (en) | 2018-07-05 |
MX2013000316A (es) | 2013-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016219738A1 (en) | Designer peptide-based PCV2 vaccine | |
RU2375374C2 (ru) | Домены и эпитопы менингококкового белка nmb1870 | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
WO2010104761A3 (en) | Anti-cd40 antibodies and uses thereof | |
EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
EA201071365A1 (ru) | Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1 | |
WO2010104747A3 (en) | Antigen presenting cell targeted vaccines | |
PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
WO2010044889A3 (en) | Torque teno virus (ttv) isolates and compositions | |
EA200701305A1 (ru) | Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида | |
EA201491123A1 (ru) | Субъединичная вакцина против цирковируса свиней типа 2 (pcv2) | |
PE20200607A1 (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
EA201170813A1 (ru) | Способы и композиции на основе pcv2 для лечения свиней | |
EA201170217A1 (ru) | Гибридные полипептидные антигены респираторно-синцитиального вируса | |
ATE522541T1 (de) | Bakterielle adhäsine konformere | |
ATE516345T1 (de) | Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen | |
ATE424450T1 (de) | Chimärische leere capside des ibdv (infectious bursal disease virus), gewinnungsverfahren und anwendungen | |
GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
JP2014502961A5 (es) | ||
EA201390998A1 (ru) | Препарат фторуглеродсвязанных пептидов | |
RU2015135619A (ru) | Рекомбинантные антигены цирковируса свиней типа 2 (pcv-2) для композиций вакцин, диагностический набор и их применение | |
AU2019208196A1 (en) | Wnt compositions and methods for purification | |
EA201291437A1 (ru) | Концентрация вакцинных антигенов без лиофилизации | |
NZ596501A (en) | Casb7439 constructs | |
WO2012036391A3 (ko) | 돼지 써코바이러스2(pcv2) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |